News - Men's Health, Actavis

Filter

Current filters:

Men's HealthActavis

Popular Filters

1 to 25 of 147 results

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

Ampio’s Vyrix unit out-licenses certain rights for Zertane to Paladin

10-04-2014

USA-based biotech firm Ampio Pharmaceuticals says its wholly-owned subsidiary Vyrix Pharmaceuticals…

Ampio PharmaceuticalsBiotechnologyEndo Health SolutionsLicensingMen's HealthPaladin LabsVyrix PharmaceuticalsZertane

Actavis opens new Asia Pacific regional headquarters in Singapore

03-04-2014

Ireland-headquartered generics major Actavis has officially opened its new regional office in Singapore…

ActavisAsia-PacificGenericsManagementMarkets & Marketing

US FTC releases 2013 highlights, including action against Actavis and Mylan

US FTC releases 2013 highlights, including action against Actavis and Mylan

01-04-2014

The US Federal Trade Commission chairwoman Edith Ramirez has released the agency’s 2013 Annual Highlights,…

ActavisMylan LaboratoriesPharmaceuticalRegulationUSA

Actavis prevails in Lialda patent dispute in USA

Actavis prevails in Lialda patent dispute in USA

31-03-2014

US generics major Actavis says that the US Court of Appeals for the Federal Circuit has reversed a lower…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsShireUSA

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Actavis in Daytrana patent settlement

Actavis in Daytrana patent settlement

20-03-2014

Generic drugs major Actavis has entered into an agreement with Noven Pharmaceuticals, a subsidiary of…

ActavisDaytranaGenericsHisamitsu PharmaLegalNeurologicalNorth AmericaNoven PharmaceuticalsPatentsUSA

Pfizer tackles Torrent over generic Viagra

Pfizer tackles Torrent over generic Viagra

19-03-2014

US pharma giant Pfizer is taking legal action against Indian drugmaker Torrent Pharmaceuticals to stop…

GenericsIndiaLegalMen's HealthPfizerPharmaceuticalTorrent PharmaceuticalsUSAViagra

Endo’s testosterone replacement Aveed gets FDA approval

Endo’s testosterone replacement Aveed gets FDA approval

06-03-2014

Endo International says its operating company Endo Pharmaceuticals has received US Food and Drug Administration…

AveedEndo PharmaceuticalsMen's HealthNorth AmericaPharmaceuticalRegulationUSA

Actavis challenges Multaq and Colcrys patents

02-03-2014

Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

20-02-2014

Acquisitive Ireland-headquartered generics major Actavis says that net revenue leapt 59% to $2.779 billion…

ActavisFinancialGenerics

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

Recordati gains certain rights to Apricus’ Vitaros

10-02-2014

Italian drugmaker Recordati has signed an exclusive license agreement with the USA’s Apricus Biosciences…

Apricus BioscienceEastern EuropeLicensingMen's HealthPharmaceuticalRecordatiRest of the WorldTurkeyVitaros

Actavis confirms generic Treanda patent challenge

Actavis confirms generic Treanda patent challenge

04-02-2014

US generics drug major Actavis confirms that it has filed an Abbreviated New Drug Application with the…

ActavisCephalonGenericsNorth AmericaOncologyPatentsTeva Pharmaceutical IndustriesTreandaUSA

FDA investigating risk of stroke, heart attack and death with testosterone products

FDA investigating risk of stroke, heart attack and death with testosterone products

03-02-2014

The US Food and Drug Administration said on Friday that it is investigating the risk of stroke, heart…

AbbVieActavisAndrodermAndroGelAxironEli LillyMen's HealthNorth AmericaPharmaceuticalRegulationResearchTestosteroneUSA

Actavis refocuses global business structure; reiterates 2014 outlook

Actavis refocuses global business structure; reiterates 2014 outlook

01-02-2014

US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of…

ActavisBoardroomFinancialGenerics

Actavis to shed another business, its Actavis Foshan unit in China

Actavis to shed another business, its Actavis Foshan unit in China

26-01-2014

US generics major Actavis revealed a second divestiture this month, saying it has signed and completed…

ActavisAsia-PacificChinaGenericsMergers & AcquisitionsZhejiang Chiral

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

Actavis to divest certain European operations to Aurobindo

Actavis to divest certain European operations to Aurobindo

18-01-2014

US generics major Actavis plans to enter into an agreement with India’s Aurobindo Pharma for the latter…

ActavisAurobindo PharmaEuropeGenericsMergers & Acquisitions

Actavis restructures, appointing industry veterans to lead US Specialty Brands business units

Actavis restructures, appointing industry veterans to lead US Specialty Brands business units

14-01-2014

US generics and specialty drugmaker Actavis has announced an updated business structure for its US Specialty…

ActavisBoardroomGenericsManagement

Ampio Pharma takes spin-out route on failure to find Zertane partner

Ampio Pharma takes spin-out route on failure to find Zertane partner

16-12-2013

US drug developer Ampio Pharmaceuticals announced that it has spun off its sexual dysfunction business…

Ampio PharmaceuticalsAmpionInflammatory diseasesMen's HealthMergers & AcquisitionsPharmaceuticalProductionVyrix PharmaceuticalsZertane

1 to 25 of 147 results

Company Spotlight

Fibrotech

Fibrotech

Back to top